Xenon Pharmaceuticals Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter report. Unless noted, amounts are U.S. dollars.
Business context
Xenon is a clinical-stage biopharmaceutical company focused on neurological disorders, particularly epilepsy. It has no marketed products and relies on collaboration and licensing revenue, equity financing, and research funding. Its lead proprietary candidate, XEN1101, is being developed for focal epilepsy; XEN496 is in Phase 3 development for pediatric KCNQ2-DEE. Partnered programs include NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $18.4 million | $32.2 million |
| Research and development expense | $75.5 million | $50.5 million |
| General and administrative expense | $22.0 million | $12.9 million |
| Loss from operations | $79.0 million | $31.3 million |
| Net loss | $78.9 million | $28.8 million |
| Net loss per common share, basic and diluted | $1.77 | $0.81 |
| Net cash used in operating activities | $69.5 million | $48.1 million |
Revenue came from collaborations, not product sales. Neurocrine accounted for 84% of FY2021 revenue and Pacira for 16%; Neurocrine accounted for all FY2020 revenue. Revenue included $5.3 million of Neurocrine milestone revenue, $6.5 million for research and development services, $3.7 million of recognized transaction price, and $3.0 million of Pacira milestones.
R&D expense rose 49% and G&A expense rose 70% year over year, reflecting expanded development programs, headcount, stock-based compensation, market research, and intellectual-property costs. Revenue fell 43%, primarily because substantially less previously deferred Neurocrine consideration was recognized. Gross margin is not applicable to the company’s reported business model; no product sales were reported.
At year-end, cash and cash equivalents were $175.7 million and marketable securities were $376.1 million, totaling $551.8 million, versus $177.0 million a year earlier. Current liabilities were $14.3 million; total liabilities were $22.0 million, principally lease liabilities. The company had no term loan outstanding, having repaid it in 2020. Operating cash outflow was $69.5 million; investing cash outflow was $246.8 million, mainly from net purchases of marketable securities; financing cash inflow was $447.5 million, largely from 2021 equity and pre-funded warrant offerings.
Management expected existing cash, cash equivalents, and marketable securities to fund operating expenses and capital requirements for at least 12 months from the filing date, while stating those resources would not fund completion of all clinical development and commercialization. The company expects significant expenses and operating losses for at least the next 12–24 months and anticipates needing additional capital over time.
Clinical and business developments; outlook
- XEN1101: The Phase 2b X-TOLE trial met its primary and key secondary endpoints. Median monthly focal-seizure reduction was 52.8%, 46.4%, and 33.2% for 25 mg, 20 mg, and 10 mg, respectively, versus 18.2% for placebo. At least 50% seizure reduction occurred in 54.5%, 43.1%, and 28.3% of those dose groups versus 14.9% for placebo. Adverse events increased with dose; common events included dizziness, somnolence, fatigue, and headache. Management planned an FDA end-of-Phase 2 meeting in Q2 2022 and estimated Phase 3 initiation in the second half of 2022. These were topline Phase 2 results, not evidence of approval.
- XEN496: The EPIK Phase 3 study was underway in approximately 40 children with KCNQ2-DEE; completion was anticipated in the first half of 2023. COVID-19 had affected site initiation and could affect enrollment.
- Partnered programs: Neurocrine was conducting Phase 2 studies of NBI-921352 in adult focal-onset seizures and pediatric SCN8A-DEE; adult data were expected in 2023. In January 2022, Xenon received a $15.0 million milestone package, comprising $6.75 million cash and an $8.25 million equity investment, following FDA acceptance of a pediatric protocol amendment. Pacira’s PCRX301 Phase 1b trial was underway, with topline data potentially available in Q2 2022.
- Other development: An investigator-sponsored Phase 2 XEN1101 study in major depressive disorder was enrolling; a larger company-sponsored study was expected to begin in the first half of 2022, subject to regulatory acceptance.
- Capital and dilution: 2021 public offerings and related issuances generated $447.3 million net. At December 31, 2021, the company also had 5.64 million options, 2.78 million pre-funded warrants, and 1.02 million convertible preferred shares outstanding, among other potential dilution.
Risks, contingencies, and unusual items
Key risks include continuing losses and future financing needs; uncertain clinical, regulatory, and enrollment outcomes; reliance on collaborators—particularly Neurocrine—and third-party manufacturers and clinical research organizations; competition; intellectual-property protection; and potential COVID-19, supply-chain, foreign-exchange, and reimbursement impacts. Milestone and royalty receipts are contingent on development and commercial success. The company reported a $3.2 million remaining Medpace service commitment, which it intended to satisfy through future services; no liability was recorded. Potential future payments to 1st Order include up to $7.4 million in development, regulatory, and other milestones. No material legal proceedings were reported. KPMG issued unqualified audit opinions on the financial statements and internal control over financial reporting; no critical audit matters were identified.
Important facts for investors to verify
- Whether XEN1101’s complete X-TOLE data support the planned Phase 3 design, dose selection, safety profile, and FDA timeline.
- Progress, enrollment, and completion timing for the XEN496 EPIK trial, including any continuing COVID-19 or site-initiation effects.
- Neurocrine’s and Pacira’s clinical progress and the timing and probability of further milestones, royalties, or other collaboration payments.
- Cash burn, investment balances, and management’s stated minimum 12-month liquidity runway against planned development spending and longer-term financing needs.
- Potential dilution from outstanding options, pre-funded warrants, preferred shares, and any future equity issuance.
- Revenue concentration and the company’s continued lack of product sales or established commercial infrastructure.